SCHEMBL4610253

SCHEMBL4610253

Cc1ccc(N2CCN(S(=O)(=O)CC(C(=O)NO)C(C)C)CC2)c(C)c1

nearest known ligand 0.49

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.49
ALDH1A1 P00352 3/20 0.49
MCOLN3 Q8TDD5 1/20 0.49
LMNA P02545 4/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
GAA P10253 1/20 0.46
POLB P06746 3/20 0.45
HTT P42858 4/20 0.44
MAPK1 P28482 1/20 0.44
MMP2 P08253 1/20 0.43
MMP13 P45452 1/20 0.43
TP53 P04637 1/20 0.43
MEN1 O00255 1/20 0.42
HPGD P15428 1/20 0.42
KMT2A Q03164 1/20 0.42
IGF1R P08069 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4610291 0.89 LMNA (0.44) MAPTALDH1A1MCOLN3LMNASMN1; SMN2
SCHEMBL4610297 0.87 MAPK1 (0.47) MAPTALDH1A1MCOLN3LMNASMN1; SMN2
SCHEMBL4610349 0.87 MAPK1 (0.47) MAPTALDH1A1MCOLN3LMNASMN1; SMN2
SCHEMBL4610549 0.86 LMNA (0.49) MAPTALDH1A1LMNASMN1; SMN2POLB
SCHEMBL4610286 0.84 POLB (0.38) MAPTLMNAPOLBMMP2MMP13
SCHEMBL4611148 0.83 TSHR (0.60) MAPTALDH1A1LMNASMN1; SMN2GAA
SCHEMBL4610312 0.82 HSD17B10 (0.43) ALDH1A1LMNASMN1; SMN2MMP13TP53
SCHEMBL4612472 0.80 HSD17B10 (0.49) MAPTALDH1A1LMNASMN1; SMN2POLB
SCHEMBL4610194 0.80 HSD17B10 (0.46) MAPTALDH1A1LMNASMN1; SMN2POLB
SCHEMBL4611167 0.79 HSD17B10 (0.60) ALDH1A1LMNASMN1; SMN2POLBMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1641771-B1 HYDROXAMATE SULFONAMIDES AS CD23 SHEDDING INHIBITORS UCB PHARMA SA (BE) 2008-10-15 EP claimed
US-20060241118-A1 Hydroxamate sulfonamides as cd23 shedding inhibitors CELLTECH R&D LIMITED (GB) 2006-10-26 US claimed
EP-1641771-A1 HYDROXAMATE SULFONAMIDES AS CD23 SHEDDING INHIBITORS Celltech R & D Limited (GB) 2006-04-05 EP claimed
WO-2004113312-A1 HYDROXAMATE SULFONAMIDES AS CD23 SHEDDING INHIBITORS CELLTECH R & D LIMITED (GB) 2004-12-29 WO claimed
EP-1641771-B1 HYDROXAMATE SULFONAMIDES AS CD23 SHEDDING INHIBITORS UCB PHARMA SA (BE) 2008-10-15 EP disclosed
US-20060241118-A1 Hydroxamate sulfonamides as cd23 shedding inhibitors CELLTECH R&D LIMITED (GB) 2006-10-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060241118-A1 Hydroxamate sulfonamides as cd23 shedding inhibitors CD22, CD2, DPP3 MAPT 4845/4885ALDH1A1 1195/4885MCOLN3 1761/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.